Search Result

Results for "

p38α/β

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (8) Autophagy (25) Casein Kinase (7) Cholinesterase (ChE) (1) Interleukin Related (8) Isotope-Labeled Compounds (1) JAK (1) JNK (3) MMP (1) Organoid (4) p38 MAPK (63) PGE synthase (1) PROTACs (2) Raf (2) Reference Standards (16) Src (2) TGF-β Receptor (4) Tie (2) TNF Receptor (8) VEGFR (5) Wnt (4) β-catenin (2)
By Research Areas:	Cancer (32) Cardiovascular Disease (2) Inflammation/Immunology (42) Metabolic Disease (7) Neurological Disease (9)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10295

SB 202190 Maximum Cited Publications 134 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .

HY-10320

Doramapimod 50+ Cited Publications BIRB 796	p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits B-Raf with an IC₅₀ of 83 nM .

HY-10403

PH-797804 5+ Cited Publications	p38 MAPK Autophagy	Inflammation/Immunology Cancer
PH-797804 is a ATP-competitive, selective *p38α/p38β* inhibitor (IC₅₀=26 nM and K_i=5.8 nM for p38α; K_i=40 nM for p38β) and does not inhibit JNK2.

HY-10328

Neflamapimod 5+ Cited Publications VX-745	p38 MAPK Autophagy	Inflammation/Immunology
Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of *p38α* inhibitor with an IC₅₀ for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.

HY-10402

Losmapimod 10+ Cited Publications GSK-AHAB; GW856553X; SB856553	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_is of 8.1 and 7.6 for p38α and p38β, respectively .

HY-16782

Pexmetinib 2 Publications Verification ARRY-614	Tie p38 MAPK Autophagy	Cancer
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-10456

TAK-715 10+ Cited Publications	p38 MAPK Casein Kinase Wnt	Inflammation/Immunology
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC₅₀s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .

HY-10401

VX-702 4 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

HY-11068

SB 239063 30+ Cited Publications	p38 MAPK Autophagy	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC₅₀ of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD. SB 239063 can penetrate the blood brain barrier (BBB) .

HY-13241A

Ralimetinib 10+ Cited Publications LY2228820	p38 MAPK Autophagy	Cancer
Ralimetinib is an ATP-competitive *p38α* and *p38β* MAPK inhibitor with an IC₅₀ of 5.3 nmol/L against human *p38α* and an IC₅₀ of 3.2 nmol/L against human *p38β*. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .

HY-10406

Talmapimod 3 Publications Verification SCIO-469	p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Talmapimod (SCIO-469) is an orally active and selective inhibitor of p38α MAPK with an IC₅₀ of 9 nM. Talmapimod inhibits the secretion of inflammatory factors (such as TNFα, *IL-1β, IL-6, and VEGF) by suppressing the p38α* MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .

HY-10295A

SB 202190 hydrochloride Maximum Cited Publications 134 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .

HY-108642

AMG-548	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548, an orally active and selective *p38α* inhibitor (K_i=0.5 nM), shows slightly selective over *p38β* (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε .

HY-14975

R1487 Hydrochloride 1 Publications Verification	p38 MAPK Autophagy	Cancer
R1487 Hydrochloride is a highly potent and selective *p38α* inhibitor, with K_d values of 0.2 nM and 29 nM for p38α and p38β, respectively .

HY-112182

UM-164 1 Publications Verification DAS-DFGO-II	Src p38 MAPK Autophagy	Cancer
UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a K_d of 2.7 nM. UM-164 also potently inhibits *p38α* and *p38β*.

HY-18303

AMG-47a 3 Publications Verification	Src VEGFR p38 MAPK JAK	Inflammation/Immunology
AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC₅₀=0.2 nM). AMG-47a inhibits VEGF2, *p38α, p38α, Jak3, MLR, and IL-2* with IC₅₀ of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as *TGF-β*, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].

HY-10405

Pamapimod 1 Publications Verification Ro4402257; R1503	p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for *p38α* and *p38β*, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

HY-18766

EW-7195 1 Publications Verification	TGF-β Receptor p38 MAPK	Cancer
EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC₅₀ of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung .

HY-N2375

L-Quebrachitol	Wnt β-catenin p38 MAPK	Metabolic Disease
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and *Wnt/β-catenin* signaling pathway .

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-108642B

AMG-548 dihydrochloride	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548 dihydrochloride, an orally active and selective *p38α* inhibitor (K_i=0.5 nM), shows slightly selective over *p38β* (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 dihydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 dihydrochloride inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε .

HY-112401

p38 MAP Kinase Inhibitor IV	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC₅₀s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .

HY-153932

NR-7h	PROTACs p38 MAPK	Cancer
NR-7h is a potent and selective *p38α* and *p38β* degrader with DC₅₀ values of 24 nM and 27.2 nM for p38α in T47D, MB-MDA-231 cells, respectively .

HY-W015445

SD-169	p38 MAPK	Metabolic Disease
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC₅₀ of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC₅₀ of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .

HY-135674

SR-318 1 Publications Verification	p38 MAPK TNF Receptor	Inflammation/Immunology Cancer
SR-318, a chemical probe, is a potent and highly selective p38 MAPK inhibitor with IC₅₀s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC₅₀ of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity .

HY-18862

PF-03715455	p38 MAPK	Inflammation/Immunology
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC₅₀ values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC₅₀=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .

HY-15505

RWJ-67657 JNJ 3026582	p38 MAPK	Cardiovascular Disease Inflammation/Immunology Cancer
RWJ-67657 (JNJ 3026582) is an orally active and selective *p38α* and p38β MAPK inhibitor with IC₅₀s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .

HY-108645

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC₅₀ of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

HY-170879

JD123	p38 MAPK JNK	Cancer
JD123 inhibits JNK1 activity and the expression of cJun (1-135). JD123 is a ATP-competitive p38-γ MAPK inhibitor, but not effect to ERK1, ERK2, or p38-α, p38-β or p38-δ. .

HY-114221

Org 48762-0 UR13870	p38 MAPK	Inflammation/Immunology
Org 48762-0 (UR13870) is a potent, orally active and selective p38 inhibitor with an EC₅₀ of 0.1 μM for p38α kinase. Org 48762-0 shows a high degree of kinase selectivity for p38α and p38β over other kinases. Org 48762-0 reduces Lipopolysaccharides (HY-D1056) (LPS)-induced TNFα release. Org 48762-0 can be used for the study of rheumatoid arthritis (RA) and Werner syndrome .

HY-10401R

VX-702 (Standard)	Reference Standards p38 MAPK Autophagy	Inflammation/Immunology
VX-702 (Standard) is the analytical standard of VX-702. This product is intended for research and analytical applications. VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

HY-108646

SX 011	p38 MAPK JNK	Inflammation/Immunology
SX 011 is a p38 inhibitor with IC₅₀s of 9 nM and 90 nM against p38α and p38β, respectively. SX 011 also inhibits JNK-2 with an IC₅₀ of 100 nM. SX-011 is orally bioavailable .

HY-114405

SJFδ	PROTACs p38 MAPK Autophagy	Cancer
SJFδ is a 10-atom linker PROTAC based on von Hippel-Lindau ligand. SJFδ degrades p38δ with a DC₅₀ of 46.17 nM, but does not degrade p38α, p38β, or p38γ .

HY-175655

BChE/p38-α MAPK-IN-1	p38 MAPK Cholinesterase (ChE) Interleukin Related	Neurological Disease Inflammation/Immunology
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC₅₀ = 772 nM) and p38α MAPK (IC₅₀ = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation .

HY-147518

p38-α MAPK-IN-5	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-5 (compound 4e) is a potent *p38α* inhibitor with IC₅₀s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-119298

AW-814141	p38 MAPK	Inflammation/Immunology
AW-814141 is a selective and orally active p38 MAP kinase inhibitor. AW-814141 has an IC₅₀ values of 100 nM and 158 nM for *p38-α* and β isoforms, respectively. AW-814141 can inhibit the production of TNF-α induced by LPS (HY-D1056). AW-814141 can inhibit paw edema in rats in a dose-dependent manner. AW-814141 exhibits anti-inflammatory activity and can be used in the research of inflammatory diseases such as rheumatoid arthritis .

HY-10320G

Doramapimod (GMP) BIRB 796 (GMP)	p38 MAPK	Cancer
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC₅₀s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity .

HY-14412

p38α inhibitor 4	p38 MAPK	Cancer
p38α inhibitor 4 (compound 10) is a selective and allosteric *p38α* inhibitor with an IC₅₀ value of 1.2 μM. p38α inhibitor 4 exhibits no activity against p38β, p38γ, and p38δ .

HY-10406A

Talmapimod hydrochloride SCIO-469 hydrochloride	p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis	Cancer
Talmapimod (SCIO-469) hydrochloride is an orally active and selective inhibitor of p38α MAPK with an IC₅₀ of 9 nM. Talmapimod hydrochloride inhibits the secretion of inflammatory factors (such as TNFα, *IL-1β, IL-6, and VEGF) by suppressing the p38α* MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod hydrochloride inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod hydrochloride can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .

HY-10402R

Losmapimod (Standard) GSK-AHAB (Standard); GW856553X (Standard); SB856553 (Standard)	Reference Standards p38 MAPK Autophagy	Inflammation/Immunology Cancer
Losmapimod (Standard) is the analytical standard of Losmapimod. This product is intended for research and analytical applications. Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively .

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase ALK5 inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-16782R

Pexmetinib (Standard) ARRY-614 (Standard)	Tie p38 MAPK Autophagy Reference Standards	Cancer
Pexmetinib (Standard) is the analytical standard of Pexmetinib. This product is intended for research and analytical applications. Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-10320R

Doramapimod (Standard) BIRB 796 (Standard)	Reference Standards p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (Standard) is the analytical standard of Doramapimod. This product is intended for research and analytical applications. Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .

HY-13478

AS1940477	p38 MAPK TNF Receptor Interleukin Related	Inflammation/Immunology
AS1940477 (Compound 3f) is an orally active p38 MAPK inhibitor. AS1940477 inhibits the enzymatic activity of recombinant *p38α* and β isoforms. AS1940477 inhibits the production of pro-inflammatory cytokines (including TNFα, *IL-1β, and IL-6*) in human synovial interstitial cells and animal models of inflammation. AS1940477 can be used in research on inflammatory diseases .

HY-N2375R

L-Quebrachitol (Standard)	Reference Standards Wnt β-catenin p38 MAPK	Metabolic Disease
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .

HY-15505R

RWJ-67657 (Standard) JNJ 3026582 (Standard)	p38 MAPK Reference Standards	Cardiovascular Disease Inflammation/Immunology Cancer
RWJ-67657 (Standard) is the analytical standard of RWJ-67657. This product is intended for research and analytical applications. RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .

HY-10405R

Pamapimod (Standard) Ro4402257 (Standard); R1503 (Standard)	Reference Standards p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod (Standard) is the analytical standard of Pamapimod. This product is intended for research and analytical applications. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

HY-10295AR

SB 202190 hydrochloride (Standard)	Organoid Reference Standards p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 (hydrochloride) (Standard) is the analytical standard of SB 202190 (hydrochloride). This product is intended for research and analytical applications. SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .

HY-171292

CK1δ-IN-9	Casein Kinase p38 MAPK	Others
CK1δ-IN-9 (Compound 8) is the inhibitor for casein kinase 1 that inhibits CK1δ with IC₅₀ of 1.4 nM. CK1δ-IN-9 inhibits *p38α* and *p38β* with IC₅₀ of 0.25 μM and 0.78 μM. CK1δ-IN-9 exhibits pharmacokinetic characteristics with a good oral bioavailability (70%) and a moderate clearance .

HY-10405S

Pamapimod-d4	Isotope-Labeled Compounds p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod-d₄ (Ro4402257-d₄) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2375

L-Quebrachitol	Natural Products other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Source Classification	Wnt β-catenin p38 MAPK
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and *Wnt/β-catenin* signaling pathway .

HY-N2375R

L-Quebrachitol (Standard)	Structural Classification Natural Products other families Plants Source Classification	Reference Standards Wnt β-catenin p38 MAPK
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .

Cat. No.	Product Name	Chemical Structure

HY-10405S

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d₄) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks